TNF and COVID-19: We recently evaluated XBB.1.5 COVID-19 vaccine-elicited immune responses in patients with inflammatory bowel disease (IBD) on biologic therapy targeting TNF (anti-TNF) or other cellular targets (non-anti-TNF) [31,32].